Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Evercore ISI from $60.00 to $50.00 in a research ...

Sneezing, fever, chills, vomiting, coughing — it’s not just one virus wreaking havoc this winter; it’s a combination of four ...

Lehigh Valley’s health networks are seeing abnormally high cases of the stomach bug that’s taking a large number of people ...

The U.S. faces a potential 'Quad-emic' with rising cases of flu, COVID, RSV, and norovirus. Older adults, especially those ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in ...

MassMutual Private Wealth & Trust FSB boosted its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 58.2% in the 4th ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.

The New York Times reports that the tentative $7.4 billion agreement with 15 states would also require those states to set aside as much as $800 million in what amounts to a legal defense fund for the ...

Flathead County continues to see an uptick of influenza cases and was home to a norovirus outbreak in December.

The S&P 500 notched a fresh record on Thursday. The broad market index gained 0.5% for its fourth positive session in a row ...